Direktif untuk semua produk yang mengandungi filgrastim dan pegfilgrastim: Amaran berkaitan risiko capillary leak syndrome (CLS) bagi pesakit kanser dan healthy donor (filgrastim) dan bagi pesakit kanser (pegfilgrastim)

NPRA Banner

Direktif untuk semua produk yang mengandungi filgrastim dan pegfilgrastim: Amaran berkaitan risiko capillary leak syndrome (CLS) bagi pesakit kanser dan healthy donor (filgrastim) dan bagi pesakit kanser (pegfilgrastim)

: Posted By Choo Sim Mei; 24 September 2014; Hits: 9685

User Rating: 2 / 5

Rating:

( 1 Rating )

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

Phone: +603-7883 5400

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

NPRA Product Status

Site Last Modified

Last Modified: Friday 20 December 2024, 19:30:56.

Online Services

QUEST3+ System

NPRA Support System

Online Public Engagement

Online Procurement Announcement

Direktif untuk semua produk yang mengandungi filgrastim dan pegfilgrastim: Amaran berkaitan risiko capillary leak syndrome (CLS) bagi pesakit kanser dan healthy donor (filgrastim) dan bagi pesakit kanser (pegfilgrastim)

More Links

More Links

DISCLAIMER

Site Last Modified

Online Services

Search

Main Menu English

Choose Your Language